Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Sandler

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
Brachytherapy|November 23, 2006
A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019W Robert Lee, Kyounghwa Bae, Colleen A Lawton, et al.
International Journal of Radiation Oncology, Biology, Physics|January 26, 2005
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?Deborah Kuban, Howard Thames, Larry Levy, et al.
Cancer|March 19, 2013
Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413Fabio L Cury, Daniel Hunt, Mack Roach, et al.
International Journal of Radiation Oncology, Biology, Physics|January 26, 2005
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995Patrick Kupelian, Deborah Kuban, Howard Thames, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2005
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA eraPatrick Kupelian, Howard Thames, Larry Levy, et al.
Cancer|July 12, 2005
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610Li-Yan Khor, Michelle Desilvio, Tahseen Al-Saleem, et al.
International Journal of Radiation Oncology, Biology, Physics|January 5, 2005
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRIPatrick W McLaughlin, Vrinda Narayana, Amichay Meirovitz, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2007
Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancerScott G Williams, Jeremy M G Taylor, Ning Liu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2003
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995Howard Thames, Deborah Kuban, Larry Levy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02Alan Pollack, James J Dignam, Dayssy A Diaz, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
Brachytherapy|November 23, 2006
A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019W Robert Lee, Kyounghwa Bae, Colleen A Lawton, et al.
International Journal of Radiation Oncology, Biology, Physics|January 26, 2005
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?Deborah Kuban, Howard Thames, Larry Levy, et al.
Cancer|March 19, 2013
Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413Fabio L Cury, Daniel Hunt, Mack Roach, et al.
International Journal of Radiation Oncology, Biology, Physics|January 26, 2005
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995Patrick Kupelian, Deborah Kuban, Howard Thames, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2005
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA eraPatrick Kupelian, Howard Thames, Larry Levy, et al.
Cancer|July 12, 2005
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610Li-Yan Khor, Michelle Desilvio, Tahseen Al-Saleem, et al.
International Journal of Radiation Oncology, Biology, Physics|January 5, 2005
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRIPatrick W McLaughlin, Vrinda Narayana, Amichay Meirovitz, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2007
Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancerScott G Williams, Jeremy M G Taylor, Ning Liu, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2003
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995Howard Thames, Deborah Kuban, Larry Levy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02Alan Pollack, James J Dignam, Dayssy A Diaz, et al.
Pageof 12